Two influential Reviews published recently: i) Biomaterials control of pluripotent stem cell fate for regenerative therapy, Prog Mater Sci. 2017, and ii) CRISPR/Cas9-based genome editing for disease modeling and therapy: opportunities for non-viral delivery. Chem Rev. 2017
Promoting angiogenesis with mesoporous microcarriers through a synergistic action of delivered silicon ion and VEGF
Prof. Kim HW granted NRF fund (300M won ~300,000$) per year up to 5 years for the research on immune- or angio-modulatory biomaterials.
A new type of cement (named 'nanocement') formulated with bioactive glass nanoparticles showed potential performance including angiogenic stimulation and osteoinductivity. The work was published in Biomaterials, 2018, 162, 183, by Kang MS et al.
A collaborative commercialization research institute, named GENTREN (GENoss + itREN) established with the supportive fund (500M/y up to 2 years) from NRF.
Gentren started to develop and commercialize dental synthetic bone graft materials and other root canal filling materials.
Our research and technologies initiated to become reality to the market throughout this project.
This was motivated by the transfer of two intellectural properties of Prof. Kim HW to biomaterials company (Genoss) with 100M won and 3% royalty